These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 9404486)
21. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015 [TBL] [Abstract][Full Text] [Related]
22. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia. Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005 [TBL] [Abstract][Full Text] [Related]
23. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia? Lichtman MA Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919 [TBL] [Abstract][Full Text] [Related]
26. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Van Etten RA Oncogene; 2002 Dec; 21(56):8643-51. PubMed ID: 12476310 [TBL] [Abstract][Full Text] [Related]
27. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Emanuel PD; Shannon KM; Castleberry RP Mol Med Today; 1996 Nov; 2(11):468-75. PubMed ID: 8947912 [TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations. Bastie JN; Aucagne R; Droin N; Solary E; Delva L Cell Mol Life Sci; 2012 Sep; 69(17):2853-61. PubMed ID: 22415325 [TBL] [Abstract][Full Text] [Related]
35. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271 [TBL] [Abstract][Full Text] [Related]
36. [Molecular mechanism and progress in treatment of juvenile myelomonocytic leukemia (JMML)]. Koike K; Matsuda K Rinsho Ketsueki; 2013 Jun; 54(6):538-44. PubMed ID: 23823092 [No Abstract] [Full Text] [Related]
37. Important therapeutic targets in chronic myelogenous leukemia. Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816 [TBL] [Abstract][Full Text] [Related]
38. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610 [TBL] [Abstract][Full Text] [Related]